Are Clinical Outcome Assessments Sufficiently Valued?

May 29, 2024

Back to all webinars

Title: Are Clinical Outcome Assessments Sufficiently Valued?

Wednesday, May 29, 2024
10:00AM EDT | 2:00PM UTC | 4:00PM CEST

Click here for time zone conversion

Register Now


This webinar is for Clinical Outcome Assessment (COA) scientists involved in developing COA strategies to generate evidence for stakeholders such as regulatory bodies, reimbursement agencies, clinicians, and patients. The webinar will also be of benefit to those interested in learning how COA data can be valued by multiple stakeholders. The discussion will focus on the challenges with developing robust Patient Reported Outcome (PRO) strategies to effectively meet the needs of all stakeholders. Additionally, it will discuss the forthcoming recommendations from SISAQOL-IMI, an international multi-stakeholder Consortium, concerning the design, analysis, and communication of PROs. 

Presenters will discuss the value of PRO data from different stakeholder perspectives and explore how SISAQOL-IMI recommendations are likely to impact their practices. More specifically, the webinar will discuss the challenges of evaluating PRO data from an HTA and regulatory perspective, reflecting the different evidentiary requirements for submissions to different HTA bodies and regulatory authorities. An industry perspective on how the SISAQOL-IMI recommendations would impact the industry practices regarding PROs will be presented. The webinar will also cover patient perspective on PROs and how patients and patient representatives are planning to use the SISAQOL-IMI recommendations. 

The aim of the webinar is to increase awareness of the challenges associated with generating PRO data and its value to different stakeholders and generate discussion to inform potential solutions to these challenges. Finally, the webinar will provide information about the content of the SISAQOL-IMI recommendations and how they can be used. 

Learning Objectives

  • Increase awareness of the complexity in developing COA strategies to meet different stakeholder requirements.
  • Develop a greater understanding of the value of COA data from diverse perspectives and identify synergies across the value of COA data among various stakeholders.
  • Greater awareness of various initiatives in development to enhance the value of COA data.



Bryan Bennett, PhD, Head of Patient-Centered Outcomes, Jazz Pharmaceuticals, Horncliffe, England, UK

Ahu Alanya, PhD, Team Lead EORTC, Quality of Life Group, Brussels, Belgium

Anders Ingelgaard, PhD, Industry Representative and Co-Lead, SISAQOL-IMI Consortium, Frankfurt, Germany

Anja Schiel, PhD, Senior Advisor, Norwegian Medicines Agency, Oslo, Norway

Hans Scheurer, MSc, Vice Chair, Workgroup of European Cancer Patient Advocacy Networks (WECAN), Nijmegen, Netherlands

Silène ten Seldam MSc, Research Assistant, Myeloma Patients Europe, Edinburgh, Scotland.


Brought to you by:
ISPOR Clinical Outcome Assessment Special Interest Group


Please note: On the day of the scheduled webinar, the first 1000 registered participants will be accepted into the webinar. For those who are unable to attend, or would like to review the webinar at a later date, the full-length webinar recording will be made available at the ISPOR Educational Webinar Series webpage approximately 2 days after the scheduled Webinar.

Reservations are on a first-come, first-served basis.


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now